International central adjudication committee in the PLATO trial: Independent body of experts or friendly family picnic?

Victor L. Serebruany, Seth D. Fortmann

Research output: Contribution to journalArticle

Abstract

The International Central Adjudication Committee (ICAC) is responsible for blinded independent assessment of complex clinical events in randomized trials. In this study, we analyze the constituence and impact of the ICAC in the PLATO trial. The PLATO ICAC was entirely governed by two academic institutions, Duke Clinical Research Institute (DCRI) and Uppsala Clinical Research Center (UCRC). Both co-chairman, all coordinators and half of the adjudicators in the PLATO ICAC belonged to either DCRI or UCRC. Among the other adjudicators representing USA, Canada and Australia, majority had DCRI ties, including at least five former Duke cardiology fellows. Furthermore, both co-chairmen are listed as adjudicators, representing obvious conflict. In the PLATO trial, the sponsor representatives were involved in selecting the ICAC members. Finally, 21 out of the 50 adjudicators represented Sweden, the homeland of the PLATO sponsor and primary investigator. Heavy selection bias in the ICAC constituence, lack of independence and potential control of the ICAC by the study sponsor may influence PLATO outcomes, and should be avoided in the future.

Original languageEnglish (US)
Pages (from-to)867-869
Number of pages3
JournalExpert Review of Cardiovascular Therapy
Volume13
Issue number8
DOIs
StatePublished - Aug 1 2015

Fingerprint

Committee Membership
Selection Bias
Cardiology
Research
Sweden
Canada
(1,2-diamino-4-nitrobenzene)dichloroplatinum(II)
Research Personnel

Keywords

  • clinical trials
  • event adjudication
  • myocardial infarction
  • ticagrelor

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Internal Medicine
  • Medicine(all)

Cite this

International central adjudication committee in the PLATO trial : Independent body of experts or friendly family picnic? / Serebruany, Victor L.; Fortmann, Seth D.

In: Expert Review of Cardiovascular Therapy, Vol. 13, No. 8, 01.08.2015, p. 867-869.

Research output: Contribution to journalArticle

@article{c5ea3da0801e4cb19462c4473a5960e0,
title = "International central adjudication committee in the PLATO trial: Independent body of experts or friendly family picnic?",
abstract = "The International Central Adjudication Committee (ICAC) is responsible for blinded independent assessment of complex clinical events in randomized trials. In this study, we analyze the constituence and impact of the ICAC in the PLATO trial. The PLATO ICAC was entirely governed by two academic institutions, Duke Clinical Research Institute (DCRI) and Uppsala Clinical Research Center (UCRC). Both co-chairman, all coordinators and half of the adjudicators in the PLATO ICAC belonged to either DCRI or UCRC. Among the other adjudicators representing USA, Canada and Australia, majority had DCRI ties, including at least five former Duke cardiology fellows. Furthermore, both co-chairmen are listed as adjudicators, representing obvious conflict. In the PLATO trial, the sponsor representatives were involved in selecting the ICAC members. Finally, 21 out of the 50 adjudicators represented Sweden, the homeland of the PLATO sponsor and primary investigator. Heavy selection bias in the ICAC constituence, lack of independence and potential control of the ICAC by the study sponsor may influence PLATO outcomes, and should be avoided in the future.",
keywords = "clinical trials, event adjudication, myocardial infarction, ticagrelor",
author = "Serebruany, {Victor L.} and Fortmann, {Seth D.}",
year = "2015",
month = "8",
day = "1",
doi = "10.1586/14779072.2015.1063419",
language = "English (US)",
volume = "13",
pages = "867--869",
journal = "Expert Review of Cardiovascular Therapy",
issn = "1477-9072",
publisher = "Expert Reviews Ltd.",
number = "8",

}

TY - JOUR

T1 - International central adjudication committee in the PLATO trial

T2 - Independent body of experts or friendly family picnic?

AU - Serebruany, Victor L.

AU - Fortmann, Seth D.

PY - 2015/8/1

Y1 - 2015/8/1

N2 - The International Central Adjudication Committee (ICAC) is responsible for blinded independent assessment of complex clinical events in randomized trials. In this study, we analyze the constituence and impact of the ICAC in the PLATO trial. The PLATO ICAC was entirely governed by two academic institutions, Duke Clinical Research Institute (DCRI) and Uppsala Clinical Research Center (UCRC). Both co-chairman, all coordinators and half of the adjudicators in the PLATO ICAC belonged to either DCRI or UCRC. Among the other adjudicators representing USA, Canada and Australia, majority had DCRI ties, including at least five former Duke cardiology fellows. Furthermore, both co-chairmen are listed as adjudicators, representing obvious conflict. In the PLATO trial, the sponsor representatives were involved in selecting the ICAC members. Finally, 21 out of the 50 adjudicators represented Sweden, the homeland of the PLATO sponsor and primary investigator. Heavy selection bias in the ICAC constituence, lack of independence and potential control of the ICAC by the study sponsor may influence PLATO outcomes, and should be avoided in the future.

AB - The International Central Adjudication Committee (ICAC) is responsible for blinded independent assessment of complex clinical events in randomized trials. In this study, we analyze the constituence and impact of the ICAC in the PLATO trial. The PLATO ICAC was entirely governed by two academic institutions, Duke Clinical Research Institute (DCRI) and Uppsala Clinical Research Center (UCRC). Both co-chairman, all coordinators and half of the adjudicators in the PLATO ICAC belonged to either DCRI or UCRC. Among the other adjudicators representing USA, Canada and Australia, majority had DCRI ties, including at least five former Duke cardiology fellows. Furthermore, both co-chairmen are listed as adjudicators, representing obvious conflict. In the PLATO trial, the sponsor representatives were involved in selecting the ICAC members. Finally, 21 out of the 50 adjudicators represented Sweden, the homeland of the PLATO sponsor and primary investigator. Heavy selection bias in the ICAC constituence, lack of independence and potential control of the ICAC by the study sponsor may influence PLATO outcomes, and should be avoided in the future.

KW - clinical trials

KW - event adjudication

KW - myocardial infarction

KW - ticagrelor

UR - http://www.scopus.com/inward/record.url?scp=84937546012&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937546012&partnerID=8YFLogxK

U2 - 10.1586/14779072.2015.1063419

DO - 10.1586/14779072.2015.1063419

M3 - Article

C2 - 26118636

AN - SCOPUS:84937546012

VL - 13

SP - 867

EP - 869

JO - Expert Review of Cardiovascular Therapy

JF - Expert Review of Cardiovascular Therapy

SN - 1477-9072

IS - 8

ER -